G9a/Glp are not commonly mutated in lung adenocarcinoma26; therefore, we analyzed G9a and Glp expression in the Directors Challenge data set from over 400 adenocarcinoma patients to determine if G9a may be linked to clinical criteria in patients. This evidence concerns the gene EHMT1 and adenocarcinoma.